By Natalie Grover LONDON/PARIS (Reuters) -French drugmaker Valneva said on Monday that the European Medicines Agency (EMA) had asked for more data on its COVID-19 vaccine, precipitating a sharp fall in its shares. The latest EMA setback comes after Britain earlier this month cleared the use of Valneva’s vaccine, becoming the first European country to give its shot the green light. Valneva said the EMA Committee for Medicinal Products for Human Use (CHMP) had a fresh list of questions, including requests for additional data and for further justification of a conditional marketing authorisation …